Theratechnologies announces 1-for-4 reverse stock split

Theratechnologies announced that its Board of Directors approved a consolidation of the issued and outstanding common shares of the Company’s share capital on the basis of one post- consolidation share for each four pre-consolidation shares issued and outstanding. The Consolidation will be effective July 31, 2023, subject to applicable regulatory approvals, including the Toronto Stock Exchange and the Nasdaq Stock Market. No shareholder approval will be required for the Consolidation to come into effect. The Company expects its common shares will begin trading on the TSX and the NASDAQ on a consolidated basis on or about July 31, 2023.